TRPH-222 Interim Phase 1 Data: Enhancing Safety with SMARTag® Technology
Summary: Maximizing the therapeutic window and manufacturing well-defined ADCs are major challenges in the clinical development of ADCs. During this webinar, experts from Triphase Accelerator and Catalent Biologics will discuss their collaboration to develop TRPH-222, the first ADC to reach the clinic using the SMARTag® site-specific conjugation technology from Catalent. TRPH-222 is a CD22-targeted ADC for the treatment of patients with B-cell lymphoma.